{
    "ticker": "CRVO",
    "name": "Correvio Pharma Corp.",
    "description": "Correvio Pharma Corp. is a global biotechnology company focused on developing and commercializing innovative therapeutics for patients with cardiovascular diseases. Established to address significant unmet medical needs within the cardiovascular space, Correvio is committed to improving the quality of life for patients suffering from conditions such as atrial fibrillation and heart failure. The company\u2019s lead product, Brinavess, is designed for the rapid conversion of recent onset atrial fibrillation to sinus rhythm, providing a crucial therapeutic option in emergency settings. Correvio operates in a highly specialized segment of the pharmaceutical industry and has a strong pipeline of additional product candidates under development, aimed at enhancing treatment options for cardiovascular patients. With a commitment to research and development, Correvio collaborates with healthcare professionals and institutions to ensure its products meet the highest standards of safety and efficacy. The company is headquartered in Vancouver, Canada, and is actively involved in expanding its market presence across various regions, including Europe and North America. Correvio\u2019s mission is to deliver innovative therapies that can transform the standard of care in cardiovascular medicine, ultimately leading to better patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, Canada",
    "founded": "2011",
    "website": "https://www.correvio.com",
    "ceo": "David S. S. M. Pritchard",
    "social_media": {
        "twitter": "https://twitter.com/CorrevioPharma",
        "linkedin": "https://www.linkedin.com/company/correvio-pharma/"
    },
    "investor_relations": "https://investors.correvio.com",
    "key_executives": [
        {
            "name": "David S. S. M. Pritchard",
            "position": "CEO"
        },
        {
            "name": "Michele C. H. Turner",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cardiovascular Therapeutics",
            "products": [
                "Brinavess"
            ]
        }
    ],
    "seo": {
        "meta_title": "Correvio Pharma Corp. | Cardiovascular Therapeutics",
        "meta_description": "Explore Correvio Pharma Corp., a biotechnology company dedicated to improving cardiovascular health through innovative therapies. Discover our leading product and pipeline.",
        "keywords": [
            "Correvio",
            "Cardiovascular",
            "Pharmaceuticals",
            "Brinavess",
            "Atrial Fibrillation"
        ]
    },
    "faq": [
        {
            "question": "What does Correvio Pharma specialize in?",
            "answer": "Correvio Pharma specializes in developing therapeutics for cardiovascular diseases."
        },
        {
            "question": "What is Brinavess?",
            "answer": "Brinavess is Correvio's lead product for the rapid conversion of atrial fibrillation to sinus rhythm."
        },
        {
            "question": "Where is Correvio Pharma headquartered?",
            "answer": "Correvio Pharma is headquartered in Vancouver, Canada."
        },
        {
            "question": "When was Correvio Pharma founded?",
            "answer": "Correvio Pharma was founded in 2011."
        }
    ],
    "competitors": [
        "AMGN",
        "ABBV",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "CELG",
        "VRTX",
        "REGN"
    ]
}